Sorafenib Tosylate Patent Expiration
Sorafenib Tosylate is Used for treating advanced renal cell carcinoma, carcinoma of the thyroid, and unresectable hepatocellular carcinoma. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Sorafenib Tosylate Patents
Given below is the list of patents protecting Sorafenib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nexavar | US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8618141 | Aryl ureas with angiogenesis inhibiting activity |
Feb 11, 2023
(Expired) | Bayer Hlthcare |
| Nexavar | US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8877933 | Thermodynamically stable form of a tosylate salt | Dec 24, 2027 | Bayer Hlthcare |
| Nexavar | US9737488 | Pharmaceutical composition for the treatment of cancer | Sep 10, 2028 | Bayer Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Sorafenib Tosylate Generics
Several generic applications have been filed for Sorafenib Tosylate. The first generic version for Sorafenib Tosylate was by Mylan Pharmaceuticals Inc and was approved on Sep 10, 2020. And the latest generic version is by Torrent Pharmaceuticals Ltd and was approved on Apr 12, 2023.
Given below is the list of companies who have filed for Sorafenib Tosylate generic.
1. TORRENT
Torrent Pharmaceuticals Ltd has filed for 1 generic for Sorafenib Tosylate. Given below are the details of the strengths of this generic introduced by Torrent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Apr 12, 2023 |
2. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Sorafenib Tosylate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Sep 10, 2020 |
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Sorafenib Tosylate. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Jun 7, 2022 |
4. YABAO PHARM
Yabao Pharmaceutical Co Ltd Beijing has filed for 1 generic for Sorafenib Tosylate. Given below are the details of the strengths of this generic introduced by Yabao Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Nov 9, 2022 |
5. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 1 generic for Sorafenib Tosylate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 200MG BASE | tablet | Prescription | ORAL | AB | Nov 12, 2020 |